Concord Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Concord Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.2K	Buy	+200	New	+$60.3K	0.01%	341
2026 Q1	–	Sell	-200	Closed	-$79.5K	–	227
2025 Q4	$79.5K	Hold	200	–	–	0.01%	279
2025 Q3	$91.2K	Hold	200	–	–	0.01%	264
2025 Q2	$65.2K	Hold	200	–	–	0.01%	312
2025 Q1	$54K	Hold	200	–	–	0.01%	308
2024 Q4	$47.1K	Hold	200	–	–	0.01%	339
2024 Q3	$55K	Hold	200	–	–	0.01%	324
2024 Q2	$48.6K	Buy	+200	New	+$31.6K	0.01%	313
2022 Q3	–	Sell	-17	Closed	-$2K	–	190
2022 Q2	$2K	Sell	17 -111	-87%	-$15.7K	﹤0.01%	985
2022 Q1	$21K	Buy	128 +9	+8%	+$1.37K	0.01%	616
2021 Q4	$20K	Buy	119 +38	+47%	+$7.06K	﹤0.01%	640
2021 Q3	$15K	Buy	81 +31	+62%	+$5.82K	0.01%	415
2021 Q2	$8K	Buy	50 +6	+14%	+$879	﹤0.01%	651
2021 Q1	$6K	Buy	+44	New	+$6.62K	﹤0.01%	642

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concord Wealth Partners's ALNY Position: Q2 2026 in Review

Concord Wealth Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 200 shares worth $60.2K. The stake represents 0.01% of the portfolio and ranks #341 among its holdings. This is a return to the name: Concord Wealth Partners previously reported a position in ALNY as recently as Q4 2025.

Concord Wealth Partners first reported a position in ALNY in Q1 2021 and has held it in 14 quarters since. The position peaked at $91.2K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Concord Wealth Partners held 200 shares of Alnylam Pharmaceuticals worth $60.2K as of Q2 2026.
Alnylam Pharmaceuticals was a new Concord Wealth Partners position in Q2 2026.
Alnylam Pharmaceuticals made up 0.01% of Concord Wealth Partners's portfolio in Q2 2026, its #341 holding.
Concord Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
Concord Wealth Partners's Alnylam Pharmaceuticals position peaked at $91.2K in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Concord Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.